Amy Mimi Lin, MD


Assistant Clinical Professor, Department of Medicine, UCSF

Phone: (415) 353-7171 (appts)
Box 1711, UCSF
San Francisco, CA 94143-1711

View on UCSF Profiles

Additional Websites


Harvard University, Cambridge, MA, AB, 1989-1993, Biology
UCLA School of Medicine, Los Angeles, CA, 1994-1996
University of Chicago, Pritzker School of Medicine, Chicago, IL MD, 1996-1999, Medicine
New York Presbyterian Hospital-Cornell, New York, NY, Internship/ residency, 1999-2002, Internal Medicine
University of California, San Francisco, San Francisco, CA, Fellowship, 2002-2005, Medicine (Hematology Oncology)
University of California, San Francisco, San Francisco, CA, Fellowship, 2005-2006, Medicine (Urologic Oncology)

Professional Experience

  • 2006-2008
    Clinical Instructor of Medicine, Division of Hematology Oncology, UCSF
  • 2006-present
    Staff physician, San Francisco Veterans Administration Medical Center (SF VAMC), Medicine (Hematology/Oncology
  • 2008-present
    Assistant Clinical Professor, Medicine, UCSF

Honors & Awards

  • 1990-1991
    Harvard College Scholarship for Academic Excellence (Harvard University)
  • 1991-1992, 1990-1991
    Elizabeth Agassiz Award for Academic Excellence (Harvard University)
  • 1991-1992
    John Harvard Scholarship for Academic Excellence (Harvard University
  • 1993
    Magna cum laude in Field of Biology (Harvard University)
  • 1994
    Dr. Ursula Mandel Scholarship (UCLA School of Medicine)
  • 1995
    Short-Term Training Program (STTP) grant (UCLA School of Medicine)
  • 1998-1999
    Calvin Fentress Research Fellowship Award, University of Chicago
  • 2004
    American Association of Clinical Research (AACR)/American Society of Clinical Oncology (ASCO) Methods in Clinical Cancer Research Workshop
  • 2005
    ASCO Multi-disciplinary Prostate Cancer Symposium Merit award
  • 2005-2006
    ASCO Young Investigator Award
  • 2007-2008
    Cancer and Leukemia Group B (CALGB) Foundation Young Investigator Award

Selected Publications

  1. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76.
    View on PubMed
  2. Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep. 2012 Jan; 27(1):3-9.
    View on PubMed
  3. Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer. 2011 Sep 15; 117(18):4194-200.
    View on PubMed
  4. Chow H, Jung A, Talbott J, Lin AM, Daud AI, Coakley FV. Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. J Comput Assist Tomogr. 2011 Jan-Feb; 35(1):86-90.
    View on PubMed
  5. Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol. 2012 Jul-Aug; 30(4):408-14.
    View on PubMed
  6. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009 Jan 15; 69(2):609-15.
    View on PubMed
  7. Lin AM, Small EJ. Prostate cancer update: 2007. Curr Opin Oncol. 2008 May; 20(3):294-9.
    View on PubMed
  8. Lin AM, Small EJ. Management of hormone refractory prostate cancer. Curr Opin Support Palliat Care. 2007 Oct; 1(3):187-91.
    View on PubMed
  9. Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 2007 Jun; 5(5):323-8.
    View on PubMed
  10. Lin AM, Small EJ. Prostate cancer update: 2006. Curr Opin Oncol. 2007 May; 19(3):229-33.
    View on PubMed
  11. Lin AM, Ryan CJ, Small EJ. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol. 2007 Mar; 61(3):243-54.
    View on PubMed
  12. Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int. 2006 Oct; 98(4):763-9.
    View on PubMed
  13. Lin AM, Hershberg RM, Small EJ. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol. 2006 Sep-Oct; 24(5):434-41.
    View on PubMed
  14. Lin AM, Rini BI, Small EJ. Clinical trials in patients with biochemically relapsed prostate cancer. BJU Int. 2006 May; 97(5):905-10.
    View on PubMed
  15. Ryan CJ, Lin AM, Small EJ. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol. 2006 May-Jun; 24(3):250-3.
    View on PubMed

Go to UCSF Profiles, powered by CTSI